Clotting vs. bleeding : the importance of pharmacologic thromboprophylaxis in IBD
Abstract
"Inflammatory bowel disease (IBD) patients are at increased risk of developing venous thromboembolism (VTE), a complication associated with significant morbidity and mortality. Despite this, pharmacologic prophylaxis (with heparin products) is still under implemented owing to both a lack of awareness of the degree of thrombotic risk and concerns over adverse events (bleeding). The following case serves to illustrate the importance of initiating pharmacologic VTE prophylaxis in a patient with active bleeding in the setting of IBD."--Introduction
Part of
Citation
Am J Hosp Med 2020 Jan;4(1):2020.003 https://doi.org/10.24150/ajhm/2020.003 Am J Hosp Med 2020 Jan;4(1):2020.003 https://doi.org/10.24150/ajhm/2020.003
Rights
OpenAccess.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.